Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy

References

• Kister I , Bacon TE , Chamot E , et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15:146-58
   PubMedGoogle Scholar
• Arroyo R , Vila C , Dechant KL . Impact of Sativex (®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 2014;3:435-44
   PubMed Web of Science ®Google Scholar
• Zwibel HL . Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009;26(12):1043-57
   PubMed Web of Science ®Google Scholar
• Kobelt G , Berg J , Lindgren P , et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
   PubMed Web of Science ®Google Scholar
• Bavikatte G , Gaber T . Approach to spasticity in general practice. Br J Med Pract 2009;2(3):29-34
   Google Scholar
• Haselkorn JK , Balsdon Richer C , Fry Welch D ; Multiple Sclerosis Council for Clinical Practice Guidelines . Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005;28(2):167-99
   PubMed Web of Science ®Google Scholar
• Stevenson VL . Rehabilitation in practice: spasticity management. Clin Rehabil 2010;24:293-304
   PubMed Web of Science ®Google Scholar
• Pérez J . Combined cannabinoid therapy via an oromucosal spray. Drugs Today(Barc) 2006;42:495-501
   PubMed Web of Science ®Google Scholar
• Wade DT , Makela P , Robson P , et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Collin C , Davies P , Mutiboko IK , et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Collin C , Ehler E , Waberzinek G , et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;12:S111-12
   Google Scholar
• Wade DT , Collin C , Stott C , Duncombe P . Meta-analysis of the effects of Sativex (nabiximols) on spasticity associated with multiple sclerosis. Mult Scler 2010;16(6):707-14
   PubMed Web of Science ®Google Scholar
• Novotna A , Mares J , Ratcliffe S , et al. A randomised, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31
   PubMed Web of Science ®Google Scholar
• Lu L , Pearce H , Roome C , et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis. Pharmacoeconomics 2012;30(12):1157-71
   PubMed Web of Science ®Google Scholar
• Slof J , Gras A . Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):525-38
   Web of Science ®Google Scholar
• All Wales Therapeutics and Toxicology Centre . AWMSG Secretariat Assessment Report. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex^®) 2.7 mg/2.5 mg oromucosal spray.; Reference number 644 (July 2014)
   Google Scholar
• National Clinical Guideline Centre . Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. Clinical guideline 186; National Institute for Health and Care Excellence (UK),London; 2014
   Google Scholar
• Sativex oromucosal spray: summary of product characteristics. Almirall; Spain: 2010
   Google Scholar
• Arroyo R , Vila C , Clissold S . Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the “5E” study. Expert Rev Pharmacoecon Outcomes Res 2011;11(2):205-13
   PubMed Web of Science ®Google Scholar
• Craig BA , Sendi PP . Estimation of the transition matrix of a discrete-time Markov chain. Health Econ 2002;11:33-42
   PubMed Web of Science ®Google Scholar
• Istituto Nazionale di Statistica . Available from: www.demo.istat.it [Last accessed January 2015]
   Google Scholar
• Flachenecker P , Henze T , Zettl UK . Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice – results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71(5–6):271-9
   PubMed Web of Science ®Google Scholar
• Flachenecker P , Henze T , Zettl UK . Long-term effectiveness and safety of Sativex (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72(1–2):95-102
   PubMed Web of Science ®Google Scholar
• Zettl UK , Henze T , Essner U , Flachenecker P . Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ 2014;15(9):953-66
   PubMed Web of Science ®Google Scholar
• Svensson J , Borg S , Nilsson P . Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 2014;129(1):13-20
   PubMed Web of Science ®Google Scholar
• Gazzetta Ufficiale Repubblica Italiana. Serie generale n. 23. Supplemento ordinario n. 8 (2013)
   Google Scholar
• Associazione Italiana Fisioterapisti . Tariffario nazionale di minima consigliato per gli onorari delle prestazioni di valutazione, riabilitazione, terapia fisica e strumentale. Valutazione Fisioterapica. Available from: www.aificampania.it [Last accessed January 2015]
   Google Scholar
• Federazione Nazionala Collegi IPASVI . Nomenclatore tariffario nazionale. Available from: www.ipasvinovara.it [Last accessed January 2015]
   Google Scholar
• Ministero della Salute . Progetto Mattoni SSN. Pronto Soccorso e sistema 118. Available from: www.nsis.salute.gov.it [Last accessed January 2015]
   Google Scholar
• Farmadati . Available from: http://www.farmadati.it [Last accessed January 2015]
   Google Scholar
• Gazzetta Ufficiale della Repubblica Italiana . Available from: www.gazzettaufficiale.it/eli/id/2013/04/30/13A03504/sg [Last accessed January 2015]
   Google Scholar
• Nance P , Schryvers O , Schmidt B , et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995;22(1):22-9
   PubMed Web of Science ®Google Scholar
• Ordia JI , Fischer E , Adamski E , Spatz EL . Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996;85(3):452-7
   PubMed Web of Science ®Google Scholar
• Becker WJ , Harris CJ , Long ML , et al. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurol Sci 1995;22(3):208-17
   PubMed Web of Science ®Google Scholar
• Hsieh JC , Penn RD . Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus 2006;21:1-6
   Google Scholar
• Erwin A , Gudesblatt M , Bethoux F , et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011;17:623-9
   PubMed Web of Science ®Google Scholar
• Centro Studi Assobiomedica. Il sistema tariffari per le prestazioni di assistenza ospedaliera. Analisi n.10 (2010
   Google Scholar
• Medtronic, Inc . 2011 Medtronic Product Performance Report. 2011. Available from: http://professional.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@neuro/documents/documents/2011-neuro-ppr.pdf [Last accessed January 2015]
   Google Scholar
• Arroyo R , Massana M , Vila C . Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci 2013;123(12):850-8
   PubMed Web of Science ®Google Scholar
• Notcutt WG . A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev 2013;14:192-9
   PubMed Web of Science ®Google Scholar
• Flachenecker P , Zettl U , Henze T . THC:CBD oromucosal spray (nabiximols) in the long term treatment of multiple sclerosis spasticity. The MOVE 2 long-term study. Mult Scler 2013;19(S1):P1121, 527
   Google Scholar
• Farrar J , Troxel AB , Stott C , et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30(5):974-85
   PubMed Web of Science ®Google Scholar
• Wade DT , Makela PM , House H , et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45
   PubMed Web of Science ®Google Scholar
• Eltayb A , Etges T , Wright S . An observational post-approval registry study of patients prescribed Sativex®. Results from clinical practice. Mult Scler 2013;19(S1):P1041; 480
   Google Scholar
• Serpel MG , Notcutt W , Collin C . Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:286-95
   Google Scholar
• Notcutt W , Langford R , Davies P , et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012;18:219-28
   PubMed Web of Science ®Google Scholar
• Farrell RA , Flisher L , Broome K , et al. Sativex: an alternative to intrathecal baclofen in patients with severe multiple sclerosis-related spasticity? Mult Scler 2013;19(S1):P650; 284
   Google Scholar
• Delhaas EM , Beersen N , Redekop WK , Klazinga NS . Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 2008;11(3):227-36
   PubMed Web of Science ®Google Scholar
• Kesselring J . Evidence-based medicine and multiple sclerosis: figures and stories. Neuroepidemiology 2010;35(2):100
   PubMed Web of Science ®Google Scholar
• Sobocki P , Pugliatti M , Lauer K , Kobelt G . Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007;13(8):1054-64
   PubMed Web of Science ®Google Scholar
• Koehler J , Feneberg W , Gorodetzky H , et al. Clinical experiences with on-label nabiximols therapy in multiple sclerosis induced spasticity. Mult Scler 2013;19(S1):P646; 281–282
   Google Scholar
• Wright S , Vachova MM , Novakova I . The effect of long-term treatment with a prescription cannabis based THC: CBD oromucosal spray on cognitive function and mood: a 12 month double blind placebo-controlled study in people with spasticity due to multiple sclerosis. Mult Scler 2013;19(S1):P1206; 572
   Google Scholar
• Paolino I , Medici D , Zagaglia S , et al. Clinical and electrophysiological measures in a cohort of multiple sclerosis patients during treatment with nabiximols for spasticity. Mult Scler 2013;19(S1):P645; 281
   Google Scholar
• Freidel M , Tiel-Wilck K , Schreiber H , et al. Resistant multiple sclerosis spasticity (MSS) treatment with THC:CBD spray and effects on driving ability. Mult Scler 2013;19(S1):P1111, 522
   Google Scholar
• Ferrè L , Sorosina M , Santoro S , et al. Efficacy, safety and response rate of nabiximols assessed in an Italian monocentric cohort. Mult Scler 2014;20(S1):P920, 469
   Google Scholar
• Lorente Fernández L , Monte Boquet E , Pérez-Miralles F , et al. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Neurología 2014;29(5):257-60
   PubMed Web of Science ®Google Scholar
• Arnal C , Carrion F . Structured diagnosis and management with THC:CBD oromucosal spray of patients with resistant multiple sclerosis spasticity. Mult Scler 2013;19(S1):P1110; 522
   Google Scholar